September 9, 2014
The Food and Drug Administration’s approval process ensures safety and efficacy for each medical therapy and each indication approved.
September 3, 2014
How can policy limit prescription pain pill abuse without impeding medical access for patients with legitimate pain?
September 2, 2014
Maximizing biologic medicine’s potential for rare disease patients means observing needed safety precautions.
August 27, 2014
In the newest move to reduce prescription opioid abuse, the U.S. Drug Enforcement Administration has reassigned hydrocodone combination products (HCPs) to Controlled Substance Schedule II.
August 21, 2014
Exchange insurance plans may make second-class citizens of patients with chronic disease, a recent Peter Pitts commentary contends.
August 19, 2014
Public television viewers around the country can tune in this month for “Learning About Pain Management,” an episode of the long-running Healthy Body, Healthy Mind series.
August 14, 2014
A group of specialty physician societies and members of AfPA’s National Physicians Biologics Working Group made a collective appeal to the Food and Drug Administration today for giving biosimilar follow-ons distinct names.
August 12, 2014
A bill recently passed in the U.S. House of Representatives could help members of the prescription drug supply chain comply with controlled substances law – and ensure patients access to the medications they need.
August 6, 2014
The FDA’s first biosimilar approval application has stirred high hopes among some members of the health care community – and heated debate among others.
August 5, 2014
Real world data (RWD) provides valuable insight for improving health care, a new report from the Galen Institute contends.
